Mo1511 - The Esophageal Hypersensitivity Scale (Ehs) is a Reliable and Valid Patient-Reported Assessment Tool

2018 ◽  
Vol 154 (6) ◽  
pp. S-735
Author(s):  
Tiffany Taft ◽  
Joseph Triggs ◽  
Dustin Carlson ◽  
Alyse R. Bedell ◽  
Laurie Keefer ◽  
...  
Keyword(s):  
Assessment Tool ◽  
Patient Reported ◽  
Esophageal Hypersensitivity

Application of a Computer Vision Tool for Automated Glottic Tracking to Vocal Fold Paralysis Patients

2021 ◽  
pp. 019459982198960
Author(s):  
Tiffany V. Wang ◽  
Nat Adamian ◽  
Phillip C. Song ◽  
Ramon A. Franco ◽  
Molly N. Huston ◽  
...  
Keyword(s):  
Vocal Fold ◽  
Assessment Tool ◽  
Medical Center ◽  
Characteristic Curve ◽  
Academic Medical Center ◽  
Vocal Fold Paralysis ◽  
Control Group ◽  
Large Patient ◽  
Patient Reported ◽  
Before And After

Objectives (1) Demonstrate true vocal fold (TVF) tracking software (AGATI [Automated Glottic Action Tracking by artificial Intelligence]) as a quantitative assessment of unilateral vocal fold paralysis (UVFP) in a large patient cohort. (2) Correlate patient-reported metrics with AGATI measurements of TVF anterior glottic angles, before and after procedural intervention. Study Design Retrospective cohort study. Setting Academic medical center. Methods AGATI was used to analyze videolaryngoscopy from healthy adults (n = 72) and patients with UVFP (n = 70). Minimum, 3rd percentile, 97th percentile, and maximum anterior glottic angles (AGAs) were computed for each patient. In patients with UVFP, patient-reported outcomes (Voice Handicap Index 10, Dyspnea Index, and Eating Assessment Tool 10) were assessed, before and after procedural intervention (injection or medialization laryngoplasty). A receiver operating characteristic curve for the logistic fit of paralysis vs control group was used to determine AGA cutoff values for defining UVFP. Results Mean (SD) 3rd percentile AGA (in degrees) was 2.67 (3.21) in control and 5.64 (5.42) in patients with UVFP ( P < .001); mean (SD) 97th percentile AGA was 57.08 (11.14) in control and 42.59 (12.37) in patients with UVFP ( P < .001). For patients with UVFP who underwent procedural intervention, the mean 97th percentile AGA decreased by 5 degrees from pre- to postprocedure ( P = .026). The difference between the 97th and 3rd percentile AGA predicted UVFP with 77% sensitivity and 92% specificity ( P < .0001). There was no correlation between AGA measurements and patient-reported outcome scores. Conclusions AGATI demonstrated a difference in AGA measurements between paralysis and control patients. AGATI can predict UVFP with 77% sensitivity and 92% specificity.

Assessing Patient Symptoms Due to Nasal Septal Perforation: Development and Validation of the NOSE-Perf Scale

2021 ◽  
pp. 019459982199201
Author(s):  
Cullen M. Taylor ◽  
Stephen F. Bansberg ◽  
Michael J. Marino
Keyword(s):  
Nasal Obstruction ◽  
Discriminant Validity ◽  
Assessment Tool ◽  
Tertiary Care ◽  
Control Group ◽  
Septal Perforation ◽  
Specific Symptom ◽  
Nose Scale ◽  
Nasal Septal Perforation ◽  
Patient Reported

Objective Reporting patient symptoms due to nasal septal perforation (NSP) has been hindered by the lack of a validated disease-specific symptom score. The purpose of this study was to develop and validate an instrument for assessing patient-reported symptoms related to NSP. Study Design Validation study. Setting A tertiary care center. Methods The Nasal Obstruction Symptom Evaluation (NOSE) scale was used as an initial construct to which 7 nonobstruction questions were added to measure septal perforation symptoms. The proposed NOSE-Perf instrument was distributed to consecutive patients evaluated for NSP, those with nasal obstruction without NSP, and a control group without rhinologic complaints. Questionnaires were redistributed to the subgroup with NSP prior to treatment of the perforation. Results The study instrument was completed by 31 patients with NSP, 17 with only nasal obstruction, and 22 without rhinologic complaint. Internal consistency was high throughout the entire instrument (Cronbach α = 0.935; 95% CI, 0.905-0.954). Test-retest reliability was demonstrated by very strong correlation between questionnaires completed by the same patient at least 1 week apart ( r = 0.898, P < .001). Discriminant validity was confirmed via a receiver operating characteristic ( P < .001, area under the curve = 0.700). The NOSE-Perf scale was able to distinguish among all 3 study groups ( P < .001) and between NSP and nasal obstruction ( P = .024). When used alone, the NOSE scale could not discriminate between NSP and nasal obstruction ( P = .545). Conclusions The NOSE-Perf scale is a validated and reliable clinical assessment tool that can be applied to adult patients with NSP.

What does social isolation have to do with my arthritis? Patient and provider views of the implementation of an electronic Social Determinants of Health risk assessment tool

2020 ◽  
Vol 64 (1) ◽  
pp. 707-710
Keyword(s):  
Electronic Health Record ◽  
Social Determinants Of Health ◽  
Social Determinants ◽  
Assessment Tool ◽  
Determinants Of Health ◽  
Health Record ◽  
Institute Of Medicine ◽  
Patient Reported ◽  
Item Responses ◽  
Electronic Health

Social Determinants of Health (SDoH) are the conditions in which people are born, live, learn, work, and play that can affect health, functioning, and quality-of-life outcomes. The Institute of Medicine charged healthcare institutions with capturing and measuring patient SDoH risk factors through the electronic health record. Following the implementation of a social determinants of health electronic module across a major health institution, the response to institutional implementation was evaluated. To assess the response, a multidisciplinary team interviewed patients and providers, mapped the workflow, and performed simulated tests to trace the flow of SDoH data from survey item responses to visualization in EHR output for clinicians. Major results of this investigation were: 1) the lack of patient consensus about value of collecting SDOH data, and 2) the disjointed view of patient reported SDoH risks across patients, providers, and the electronic health record due to the way data was collected and visualized.

scholarly journals BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
A. Barnadas ◽  
◽  
M. Muñoz ◽  
M. Margelí ◽  
J. I. Chacón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Health Status ◽  
Bone Metastasis ◽  
Assessment Tool ◽  
Metastatic Breast ◽  
Perceived Health ◽  
Perceived Health Status ◽  
Patient Reported

Abstract Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Methods Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Results Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. Conclusions BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. Trial registration NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

Patient-Reported Outcomes Following Ventral Hernia Repair: Designing a Qualitative Assessment Tool

2017 ◽  
Vol 11 (2) ◽  
pp. 225-234 ◽  
Author(s):  
Martin J. Carney ◽  
Kate E. Golden ◽  
Jason M. Weissler ◽  
Michael A. Lanni ◽  
Andrew R. Bauder ◽  
...  
Keyword(s):  
Hernia Repair ◽  
Ventral Hernia ◽  
Patient Reported Outcomes ◽  
Ventral Hernia Repair ◽  
Assessment Tool ◽  
Qualitative Assessment ◽  
Patient Reported

Utility of a Patient-Reported Symptom and Functioning Assessment Tool for Geriatric Oncology Care in China

2022 ◽  
Vol 29 ◽  
pp. 28-35
Author(s):  
Dong Xue ◽  
Pingping Li ◽  
Tsun Hsuan Chen ◽  
Qiuling Shi ◽  
Xin Shelley Wang
Keyword(s):  
Assessment Tool ◽  
Geriatric Oncology ◽  
Patient Reported ◽  
Oncology Care ◽  
Functioning Assessment

Health Literacy and Patient -Reported Outcomes

2018 ◽  
pp. 109-123 ◽  
Author(s):  
Maria Irene Bellini ◽  
Andre Kubler
Keyword(s):  
Patient Reported Outcomes ◽  
Assessment Tool ◽  
Quality Care ◽  
Care Quality ◽  
Negative Effects ◽  
Patient Centered ◽  
Subjective Data ◽  
Care Plans ◽  
Patient Reported ◽  
Satisfaction Rates

Modern healthcare needs to identify parameters for high-quality care. Quality improvement is the key for advancing in healthcare, and the new assessment tool shifts from a disease-centered outcome to a patient-centered outcome. Clinical outcome such as morbidity and mortality are directly connected and interdependent from patient-reported outcomes: well-informed patients who decide with their healthcare provider what treatment is best for them have better outcomes and higher patient satisfaction rates. These subjective data collected by rigorous, meaningful, and scientific methods and presented in a utilizable format can be used to create care objectives towards which both the surgeon and their patient can travel. Time has come to carry patient-centered outcomes from research into decision making and daily care plans. This chapter outlines a focus beyond life-prolonging therapy, aiming to minimize the negative effects of treatment, optimize quality of life, and align medical decisions with patient expectations.

scholarly journals P29 A smartphone application to monitor nausea in pediatric cancer patients during chemotherapy

2019 ◽  
Vol 104 (6) ◽  
pp. e29.1-e29
Author(s):  
A Eliasen ◽  
MK Abildtoft ◽  
NS Krogh ◽  
JS Brok ◽  
R Mathiasen ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Pediatric Cancer ◽  
Assessment Tool ◽  
Smartphone Application ◽  
List Type ◽  
Notification System ◽  
Pediatric Cancer Patients ◽  
Patient Reported ◽  
User Friendly ◽  
Nausea Severity

BackgroundNausea is a common and distressing side effect for children in chemotherapy. Antiemetic recommendations are based on limited literature and prospective evaluation of antiemetic efficacy is required. Smartphone applications (apps) may collect patient-reported outcomes with precision and effectiveness1. We developed a smartphone app to track nausea in pediatric cancer patients during chemotherapy.MethodsMedical researchers, pediatric oncologists and software engineers worked synergistically in the development. We translated the validated Pediatric Nausea Assessment Tool to score nausea severity2. We conducted three rounds of patient-feedback and modification.ResultsThe app has a definition module where the child centers the attention to the concept of nausea. The child can then express nausea severity with four faces and the child’s own definition of nausea is incorporated in the question2. The app includes a notification system to ensure high response rates. All participants felt that the app was user-friendly, intuitive and that time spent was acceptable.ConclusionThe app is a user-friendly tool to assess nausea in pediatric cancer patients that can ease future pediatric antiemetic trials.ReferencesStone AA, Shiffman S, Schwartz JE, et al. Patient compliance with paper and electronic diaries. Control Clin Trials 2003 Apr;24(2):182–99.Dupuis LL, Taddio A, Kerr EN, et al. Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy 2006;26:1221–31.Disclosure(s)Nothing to disclose

Proposal of a Functional Impairment Symptom Scale for Concussion

2020 ◽  
Vol 35 (14) ◽  
pp. 983-988
Author(s):  
Matthew T. McCarthy ◽  
Sarah Janse ◽  
Natalie M. Pizzimenti ◽  
Anthony K. Savino ◽  
Brian Crosser ◽  
...  
Keyword(s):  
Functional Impairment ◽  
Assessment Tool ◽  
Pearson Correlation ◽  
Hazard Ratio ◽  
Symptom Scale ◽  
Prospective Longitudinal Study ◽  
Point Increase ◽  
Patient Reported ◽  
Sport Concussion ◽  
Prospective Longitudinal

Clinicians currently administer patient-reported symptom scales to quantify and track concussion symptoms. These scales are based on subjective ratings without reference to the degree of functional impairment caused by the symptoms. Our objective was to develop a concussion symptom scale based on functional impairment and compare it to a widely used concussion symptom checklist. We conducted a retrospective chart review evaluating 133 patients age 9-22 with an acute concussion who completed 2 symptom checklists at their initial visit—the Sport Concussion Assessment Tool (SCAT-3) symptom evaluation (22 symptoms, 0-6 scale) and the proposed Functional Impairment Scale (22 symptoms, 0-3 scale related to degree of functional impairment). Mean total symptom score was 27.2±22.9 for Sport Concussion Assessment Tool–3 and 14.7±11.9 for the Functional Impairment Scale. Pearson correlation between the scales was 0.98 ( P < .001). Mean time from concussion to first visit was 6.9±6.2 days, and median clearance time after injury was 19 (95% CI 16-21) days. After adjusting for patient and injury characteristics, an increased score on each scale was associated with longer time to clearance (5-point increase in Sport Concussion Assessment Tool–3 hazard ratio 0.885, 95% CI 0.835-0.938, P < .001; 2.5-point increase in Functional Impairment Scale hazard ratio 0.851, 95% CI 0.802-0.902, P < .001). We propose a concussion symptom scale based on functional impairment that correlates strongly with the Sport Concussion Assessment Tool–3 scale, demonstrates a similar association with time to clearance, and may provide a more intuitive approach to monitoring how symptoms are affecting patients recovering from concussion. Future research should aim to validate this scale through a prospective longitudinal study.

Sign in / Sign up

Export Citation Format

Share Document